Literature DB >> 29254803

Clinical implementation of radiosurgery using the Helical TomoTherapy unit.

Cheng B Saw1, Carol Gillette2, Christopher A Peters3, Lawrence Koutcher2.   

Abstract

The American Society of Radiation Oncology has recently recommended the use of radiosurgery to manage brain metastases. For such a recommendation to be implemented in a widespread manner, radiosurgery must be accessible at community radiation therapy facilities. The work presented here describes our clinical experience in the implementation of radiosurgery using a Helical TomoTherapy unit. Helical TomoTherapy is a unique dose-delivery system designed to perform intensity-modulated radiation therapy (IMRT). The system built on the ring-based gantry has the tight machine tolerances required for radiosurgery. A frameless system consisting of a thermoplastic mask and a noninvasive "stereotactic radiosurgery (SRS)-stereotactic radiotherapy (SRT)" fixation device is used for patient immobilization. Treatment planning is performed using the TomoHD treatment planning system designed for IMRT. The image-guidance system on the Helical TomoTherapy is used for patient localization. Our clinical experience demonstrated that the radiosurgery procedure can be streamlined as we do for IMRT patients. The treatment time of about 10 minutes is comparable with that for IMRT patients. The same patient-specific quality assurance for IMRT is used for radiosurgery. As demonstrated, SRS using Helical TomoTherapy is not a whole-day event, unlike SRS using other dose-delivery systems or SRS performed in the past.
Copyright © 2017 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brain metastases; Helical TomoTherapy; IMRT; Radiosurgery; SRS; Tomotherapy

Mesh:

Year:  2017        PMID: 29254803     DOI: 10.1016/j.meddos.2017.10.004

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  1 in total

1.  The new SRS/FSRT technique HyperArc for benign brain lesions: a dosimetric analysis.

Authors:  Hsiu-Wen Ho; Ching-Chieh Yang; Hsiu-Man Lin; Hsiao-Yun Chen; Chun-Chiao Huang; Shih-Chang Wang; Yu-Wei Lin
Journal:  Sci Rep       Date:  2021-10-26       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.